Trevi Therapeutics (TRVI) Shareholder's Equity Growth (1y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.07% |
| Dec 31, 2025 | 83.90% |
| Sep 30, 2025 | 221.84% |
| Jun 30, 2025 | 199.96% |
| Mar 31, 2025 | 37.50% |
| Dec 31, 2024 | 20.71% |
| Sep 30, 2024 | -34.19% |
| Jun 30, 2024 | -30.40% |
| Mar 31, 2024 | -28.90% |
| Dec 31, 2023 | -23.18% |
| Sep 30, 2023 | -18.46% |
| Jun 30, 2023 | 57.11% |
| Mar 31, 2023 | 872.30% |
| Dec 31, 2022 | 529.34% |
| Sep 30, 2022 | 865.76% |
| Jun 30, 2022 | 241.20% |
| Mar 31, 2022 | -55.82% |
| Dec 31, 2021 | -37.41% |
| Sep 30, 2021 | -68.05% |
| Jun 30, 2021 | -55.70% |
| Mar 31, 2021 | -49.39% |
| Dec 31, 2020 | -49.98% |
| Sep 30, 2020 | -41.33% |
| Jun 30, 2020 | -40.86% |
| Mar 31, 2020 | 140.53% |
| Dec 31, 2019 | 149.82% |
| Sep 30, 2019 | 159.33% |
| Jun 30, 2019 | 171.01% |
| Mar 31, 2019 | -29.08% |